Natural killer cell-mediated ablation of metastatic liver tumors by hydrodynamic injection of IFNα gene to mice

International Journal of Cancer

Volumn 120, Issue 6, 2007, Pages 1252-1260

  Takehara, Tetsuo ^a   Uemura, Akio ^a   Tatsumi, Tomohide ^a   Suzuki, Takahiro ^a   Kimura, Ritsuko ^a   Shiotani, Ai ^a   Ohkawa, Kazuyoshi ^a   Kanto, Tatsuya ^a   Hiramatsu, Naoki ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adaptive; DNA; Immunity NK; Innate

Indexed keywords

ANTIBODY; GANGLIOTETRAOSYLCERAMIDE; GRANZYME B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NAKED DNA; RECOMBINANT ALPHA INTERFERON; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CANCER RESISTANCE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HYDRODYNAMICS BASED TRANSFECTION; INNATE IMMUNITY; LIVER CANCER; LIVER METASTASIS; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE;

ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GENE THERAPY; INJECTIONS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LIVER; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; T-LYMPHOCYTE SUBSETS;

EID: 33846979450     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22152     Document Type: Article

References (39)

1. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol 2002;29:107-18.
2. Ruan DT, Warren RS. Liver-directed therapies in colorectal cancer. Semin Oncol 2005;32:85-94.
3. Seki S, Habu Y, Kawamura T, Takeda K, Dobashi H, Ohkawa T, Hiraide H. The liver as a crucial organ in the first line of defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag T+ cells in T helper 1 immune responses. Immun Rev 2000;174:35-46.
4. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-14.
5. Taniguchi T, Takaoka A. The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002;14:111-6.
6. Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M. Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-48.
7. Biron CA. Interferon α and β as immune regulators: a new look. Immunity 2001;14:661-4.
8. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-50.
9. Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STA signaling pathway. Cell 1996;84:431-42.
10. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. Biological consequences of STAT1-independent IFN signaling. Proc Natl Acad Sci USA 2001;98:6680-5.
11. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998;95:14411-6.
12. Coleman M, Muller S, Quezada A, Mendiratta SK, Wang J, Thull NM, Bishop J, Matar M, Mester J, Pericle F. Nonviral interferon α gene therapy inhibits growth of established tumors by eliciting a systemic immune response. Hum Gene Ther 1998;9:2223-30.
13. Horton HM, Anderson D, Hernandez P, Barnhart KM, Norman JA, Parker SE. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon a. Proc Natl Acad Sci USA 1999;96:1553-8.
14. Li S, Zhang X, Xia X, Zhou L, Breau R, Suen J, Hanna E. Intramuscular electroporation delivery of IFN-α gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 2001;8:400-7.
15. Kobayashi N, Kuramoto T, Chen S, Watanabe Y, Takakura Y. Therapeutic effect of intravenous interferon gene delivery with naked plasmid DNA in murine metastasis models. Mol Ther 2002;6:737-44.
16. Yoshimoto T, Okamura H, Tagawa Y, Iwakura Y, Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 1997;94:3948-53.
17. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, Sugimoto Y, Sasaki Y, Hori M, Hayashi N. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 2003;106:81-9.
18. Harle P, Noisakran S, Carr DJ. The application of a plasmid DNA encoding IFN-α 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. J Immunol 2001;166:1803-12.
19. Takehara T, Suzuki T, Ohkawa K, Housui A, Jinushi M, Miyagi T, Tatsumi T, Kanazawa Y, Hayashi N. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J Hepatol 2006;44:267-74.
20. Miyagi T, Takehara T, Tatsumi T, Suzuki T, Jinushi M, Kanazawa Y, Hiramatsu N, Kanto T, Tsuji S, Hori M, Hayashi N. Concanavarin A injection activates intrahepatic innate immune cells to provoke an anti-tumor effect in murine liver. Hepatology 2004;40:1190-6.
21. Liu F, Song YK, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-66.
22. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injection of naked plasmid DNA. Hum Gene Ther 1999;10:1735-7.
23. Sareneva T, Matikainen S, Kurimoto M, Julkunen I. Influenza A virus-induced IFN-α/β and IL-18 synergistically enhance IFN-γ gene expression in human T cells. J Immunol 1998;160:6032-8.
24. Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, Ahmed R, Biron CA. Two roads diverged: interferon α/β- and interleukin 12-mediated pathways in promoting T cell interferon γ responses during viral infection. J Exp Med 1999;189:1315-28.
25. Danska JS, Holland DP, Mariathasan S, Williams KM, Guidos CJ. Biochemical and genetic defects in the DNA-dependent protein kinase in murine acid lymphocytes. Mol Cell Biol 1996;16:5507-17.
26. Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factors Rev 2002;13:95-109.
27. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB, Yang NS. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 1995;92:2889-93.
28. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000;174:5-20.
29. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J et al. The anti-tumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J Clin Invest 2003;112:170-80.
30. Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, Braet F, Wisse E. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 2002;72:668-76.
31. Lee C-K, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000;165:3571-4.
32. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O'Shea JJ, Biron CA. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 2002;297:2063-6.
33. Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA 1998;95:15623-8.
34. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-34.
35. Kirkwood J. Cancer immunotherapy: the interferon-α experience. Semin Oncol 2002;29:18-26.
36. Grem JL, van Groeningen CJ, Ismail AA, Johnston PG, Alexander HR, Allegra CJ. The role of interferon-α as a modulator of fluorouracil and leucovorin. Eur J Cancer 1995;31A:1316-20.
37. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N. Phase II trial of fluorouracil and recombinant interferon α-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9:1806-10.
38. Dufour P, Husseini F, Dreyfus B, Cure H, Martin C, Prevost G, Olivier JP, Dumas F, Duclos B, Olivares R, Leszler A, Bergerat JP et al. 5-fiuorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma, a randomized study. Ann Oncol 1996;7:575-9.
39. Link KH, Kornmann M, Staib L, Redenbacher M, Kron M, Beger HG. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-α. Ann Surg 2005;242:178-87.